First time available for research use

RSV protein F-antibody

Palivizumab antibody from Synagis®

Therapeutic RSV protein F-antibody from the original Synagis® commercial drug targeting the RSV protein F-antigen, also referred to as Synagis® or palivizumab antibody. Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.

Choose your antibody
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

Product Reference

Drug nameSynagis®
INNPalivizumab
API typePalivizumab is a recombinant humanised monoclonal antibody produced by DNA technology in mouse myeloma host cells.
Pharmacotherapeutic group
Immune sera immunoglobulins, specific immunoglobulins
ATC code
J06BB16
Target of antibody
RSV protein F
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Palivizumab is a humanised IgG1κ monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV). This humanised monoclonal antibody is composed of human (95%) and murine (5%) antibody sequences. It has potent neutralising and fusion-inhibitory activity against both RSV subtype A and B strains.
Palivizumab serum concentrations of approximately 30 μg/ml have been shown to produce a 99% reduction in pulmonary RSV replication in the cotton rat model.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers
EU/1/99/117/001 - 004
Marketing authorisation holder
AbbVie Ltd
Maidenhead
SL6 4UB
United Kingdom
Name of the manufacturer of the biological active substance
Boehringer Ingelheim Pharma GmbH & Co. KG
D-88397 Biberach an der Riss
Germany

MedImmune, LLC
660 MedImmune Court / 633 Research Court, Frederick, Maryland,
USA
Name and address of the manufacturer(s) responsible for batch releaseAbbVie S .r.l. 04011 Campoverde di Aprilia(Latina)
Italy
Max shelf life
48 months
Storage conditions
2°C – 8°C
List of excipients
Powder:
Histidine
Glycine
Mannitol (E421)
Solvent:
Water for injections